EP1274302A1 - Cyclohexandiol kryoprotektor verbindungen - Google Patents

Cyclohexandiol kryoprotektor verbindungen

Info

Publication number
EP1274302A1
EP1274302A1 EP01928591A EP01928591A EP1274302A1 EP 1274302 A1 EP1274302 A1 EP 1274302A1 EP 01928591 A EP01928591 A EP 01928591A EP 01928591 A EP01928591 A EP 01928591A EP 1274302 A1 EP1274302 A1 EP 1274302A1
Authority
EP
European Patent Office
Prior art keywords
cryopreservation composition
cryopreservation
cyclohexanediol
compound
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP01928591A
Other languages
English (en)
French (fr)
Other versions
EP1274302B1 (de
Inventor
Kelvin G. M. Brockbank
Michael J. Taylor
Lia Hanson Campbell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organ Recovery Systems Inc
Original Assignee
Organ Recovery Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organ Recovery Systems Inc filed Critical Organ Recovery Systems Inc
Publication of EP1274302A1 publication Critical patent/EP1274302A1/de
Application granted granted Critical
Publication of EP1274302B1 publication Critical patent/EP1274302B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to particular cyclohexanediol molecules and their use as cryoprotectants.
  • Cryobiology may be defined as the study of the effects of temperatures of lower than normal physiologic ranges upon biologic systems.
  • the fundamentals of the science of cryobiology have evolved to the point where low temperatures are now used extensively as a means to protect and preserve biological systems during enforced periods of ischemia and hypoxia.
  • preservation is achieved using either hypothermia without freezing, or cryopreservation in which the aqueous system sustains a physical phase change with the formation of ice.
  • survival of cells from the rigors of freezing and thawing in cryopreservation procedures is only attained by using appropriate cryoprotective agents (CPAs) and in general, these techniques are applicable to isolated cells in suspension or small aggregates of cells in simple tissues. More complex tissues and organs having a defined architecture are not easily preserved using conventional cryopreservation techniques, which is principally due to the deleterious effects of ice formation in an organized multicellular tissue. Simply freezing cells or tissues results in dead, nonfunctional materials.
  • cryobiology A basic principle of cryobiology is that the extent of freezing damage depends upon the amount of free water in the system and the ability of that water to crystallize during freezing. Many types of isolated cells and small aggregates of cells can be frozen simply by following published procedures, but obtaining reproducible results for more complex tissues requires an understanding of the major variables involved in tissue cryopreservation.
  • Major variables involved in tissue freezing include (1) freezing-compatible pH buffers, (2) cryoprotectant choice, concentration and administration, (3) cooling protocol, (4) storage temperature, (5) warming protocol and (6) cryoprotectant elution.
  • cryoprotectants have been discovered. See, for example, Brockbank, supra. Cryoprotectant selection for cryopreservation is usually restricted to those that confer cryoprotection in a variety of biological systems. On occasion, combinations of cryoprotectants may result in additive or synergistic enhancement of cell survival. Comparison of chemicals with cryoprotectant properties reveals no common structural features. These chemicals are usually divided into two classes: (1) intracellular cryoprotectants with low molecular weights that penetrate cells, and (2) extracellular cryoprotectants with relatively high molecular weights (greater than or equal to sucrose (342 daltons)) which do not penetrate cells.
  • Intracellular cryoprotectants such as glycerol and dimethyl sulfoxide at concentrations from 0.5 to 3 molar, are effective in minimizing cell damage in many slowly frozen biological systems.
  • Extracellular cryoprotective agents such as polyvinylpyrrolidone or hydroxyethyl starch are often more effective at protecting biological systems cooled at rapid rates.
  • cryoprotectant materials that increase cell viability during cryopreservation.
  • SUMMARY OF THE INVENTION It is therefore one object of the present invention to provide a cryoprotectant material that effectively protects cells during cryopreservation and achieves increased cell viability upon warming from a frozen state.
  • AFPs naturally occurring anti-freeze proteins
  • the present invention relates to the use of newly discovered cryoprotectant compounds.
  • the invention relates to the use of cyclohexanediol compounds, specifically the cis or trans forms of 1,3-cyclohexanediol (1,3CHD) and 1,4-cyclohexanediol (1,4CHD), and their racemic mixtures, as cryoprotectants in preserving living cells.
  • cells to be cryopreserved are protected against the effects of cryopreservation by bringing the cells into contact with a cryopreservation composition containing at least one cyclohexanediol compound, and subsequently reducing the temperature of the cells to the cryopreservation temperature.
  • the cryopreservation composition preferably comprises not only at least one cyclohexanediol compound, but also at least one additional cryoprotectant compound and/or at least one anti-freeze protein.
  • Figure 1 is a flow chart summarizing the cryopreservation procedure utilized in obtaining the results summarized in this application.
  • Figures 2-3 are plots of relative cell viability after freezing using CHD compounds in conjunction with conventional cryoprotective agents.
  • Figures 4-5 are plots of relative cell viability after freezing using
  • Cryopreservation i.e., the preservation of cells by freezing
  • Cryopreservation typically involves freezing cells to temperatures well below freezing, for example to -130°C or less.
  • the cryopreservation temperature should be less than -20°C, more preferably -80°C or less, most preferably -130°C or less.
  • the cells to be cryopreserved using the CHD cryoprotectant compounds of the invention may be in suspension, may be attached to a substrate, etc., without limitation.
  • the cells to be protected during cryopreservation are first brought into contact with a cryopreservation composition.
  • a cryopreservation composition By being brought into contact with the cryopreservation composition is meant that the cells are made to be in contact in some manner with the cryopreservation composition so that during the reduction of temperature to the cryopreservation temperature, the cells are protected by the cryopreservation composition.
  • the cells may be brought into contact with the cryopreservation composition by filling the appropriate wells of a plate to which the cells to be protected are attached, by suspending the cells in a solution of the cryopreservation composition, etc.
  • the cells to be cryopreserved should also preferably be in contact with freezing compatible pH buffer comprised most typically of at least a basic salt solution, an energy source (for example, glucose) and a buffer capable of maintaining a neutral pH at cooled temperatures.
  • an energy source for example, glucose
  • a buffer capable of maintaining a neutral pH at cooled temperatures include, for example, Dulbecco's Modified Eagle Medium (DMEM). This material may also be included as part of the cryopreservation composition.
  • DMEM Dulbecco's Modified Eagle Medium
  • the cryopreservation composition of the invention must contain at least one cyclohexanediol (CHD) compound, for example the cis or trans forms of 1,3-cyclohexanediol or 1,4-cyclohexanediol and racemic mixtures thereof.
  • the CHD compound is present in the cryopreservation composition in an amount of from, for example, 0.05 to 2.0 M, more preferably from 0.1 M to 1.0 M.
  • the cryopreservation composition also preferably includes a solution well suited for organ storage.
  • the solution can include the buffers discussed above.
  • a particularly preferred solution is, for example, EuroCollins Solution comprised of dextrose, potassium phosphate monobasic and dibasic, sodium bicarbonate and potassium chloride.
  • the cryopreservation composition contains not only the CHD compound, but also at least one additional cryoprotectant compound.
  • additional cryoprotectant compounds may include, for example, any of those set forth in Table 10.1 of Brockbank, supra, including, but not limited to, acetamide, agarose, alginate, 1-analine, albumin, ammonium acetate, butanediol, chondroitin sulfate, chloroform, choline, dextrans, diethylene glycol, dimethyl acetamide, dimethyl formamide, dimethyl sulfoxide (DMSO), erythritol, ethanol, ethylene glycol, formamide, glucose, glycerol, ⁇ -glycerophosphate, glycerol monoacetate, glycine, hydroxyethyl starch, inositol, lactose, magnesium chloride, magnesium sulfate, maltose, mannitol,
  • the cryopreservation composition includes the CHD compound, with or without an additional cryoprotectant compound, and also includes an anti-freeze protein/peptide (AFP).
  • AFPs also include anti-freeze glycoproteins (AFGPs) and insect anti-freeze, or "thermal hysteresis” proteins, (THPs).
  • AFGPs anti-freeze glycoproteins
  • THPs insect anti-freeze, or "thermal hysteresis" proteins,
  • Naturally occurring AFPs are believed to be able to bind to the prism face of developing ice crystals, thereby altering their formation. For the fishes and insects in which these proteins occur, it means a depression of their freezing point so they are able to survive under conditions that would normally cause their body fluids to freeze.
  • AFP any of the well-known AFPs may be used in the present invention in this regard. See, for example, Sicheri and Yang, Nature, 375:427-431, (1995), describing eight such proteins. Most preferably, the AFP may be, for example, AFPI
  • AFP type I AFPDI (AFP type I I) and/or AFGP.
  • the AFPs may be present in the cryopreservation composition in an amount of from, for example, 0.01 to 1 mg/mL, more preferably 0.05 to 0.5 mg/mL, of composition, for each AFP present.
  • the cells Once the cells have been contacted with the cryopreservation composition, the cells may then be frozen for cryopreservation.
  • the cryopreservation and subsequent warming of cells may be conducted in any manner, and may utilize any additional materials, well known in the art. Preferred embodiments are described in the following discussion and the Examples set forth below.
  • the cooling (freezing) protocol for cryopreservation in the present invention may be any suitable type. Many types of cooling protocols are well known to practitioners in the art.
  • the cooling protocol calls for continuous rate cooling from the point of ice nucleation to -80°C, with the rate of cooling depending on the characteristics of the cells/tissues being frozen as understood in the art (again, see Brockbank, supra).
  • the cooling rate may be, for example, -0.1 °C to -
  • the cells are cooled to about -80°C by this continuous rate cooling, they can be transferred to liquid nitrogen or the vapor phase of liquid nitrogen for further cooling to the cryopreservation temperature, which is below the glass transition temperature of the freezing solution (again, typically -130°C or less).
  • the warming protocol for taking the cells out of the frozen state may be any type of warming protocol, which are well known to practitioners in the art. Typically, the warming is done in a one-step procedure in which the cryopreserved specimen is placed into a water bath (temperature of about 37-42°C) until complete rewarming is effected. More rapid warming is also known.
  • the cryopreserved cells, particularly cryopreserved cells fixed to a substrate are warmed by way of the methods described in co-pending U.S. Application No.
  • the cryopreservation composition of the present invention that includes at least one CHD compound is surprisingly able to increase the survival of cryopreserved cells upon freezing in a cumulative manner.
  • the following examples illustrate the surprising utility of the CHD compounds as a cryoprotectant.
  • AV5 cells are derived from porcine heart valve leaflets. Hearts were obtained from pigs and the heart valve leaflets were then removed and washed several times with sterile phosphate-buffered saline (PBS). Small pieces ( ⁇ 1 mm ) were cut and placed into a 24-well microtiter plate coated with 0.2% gelatin. Dulbecco's Modified Eagle's Medium (DMEM) with 10% fetal calf serum (FCS) was added to just cover the bottom of the well and the plate was left at 37°C with 5% CO 2 in air until visible outgrowth occurred.
  • DMEM Dulbecco's Modified Eagle's Medium
  • FCS fetal calf serum
  • EuroCollins Solution consisting of dextrose, potassium phosphate monobasic and dibasic, sodium bicarbonate and potassium chloride. The plates were then cooled at the rate of -1.0°C/min to -80°C, and then further cooled with liquid nitrogen vapor and stored overnight at -135°C.
  • Alamar Blue is a fluorescent dye that measures the oxidation/reduction reactions within cells, and thus is indicative of the overall viability of the cells after exposure to cryoprotective agents.
  • a volume of 20 ⁇ l Alamar Blue was added to cells in 200 ⁇ l of DMEM (10%FCS) and the plate was incubated at 37°C for 3 hours. Fluorescence from Alamar Blue was read in a fluorescent microplate reader (Fmax fluorescent microplate reader by Molecular Dynamics) using an excitation wavelength of 544 nm and an emission wavelength of 590 nm.
  • Figure 2 relates to 1,3CHD
  • Figure 3 relates to 1,4CHD.
  • the data was normalized to the conventional cryoprotectant alone and is the mean (+/- SEM) of 12 replicates.
  • viability was significantly increased over the comparative cryopreservation compositions that contained only the conventional cryoprotectants without a CHD compound (i.e., concentration of 0.00 CHD).
  • AFP anti-freeze protein
  • FIG. 4 the relative cell viability of AV5 cells after freezing using a combination of 1 . 4CHD/AFPI/DMSO is summarized. Concentrations of the constituents included 0.5 M 1,4CHD, 0.1 mg/mL AFPI and 1 M DMSO. The graph depicts viability in the presence of 1 M DMSO alone or in combination with 1 ,4CHD or 1,4CHD plus AFPI at the above concentrations. Data was normalized to the conventional cryoprotectant (DMSO) alone and is the mean (+/- SEM) of 3 replicates.
  • DMSO conventional cryoprotectant
  • DMSO and 0.1 mg/mL for each AFP protein left bar of graph is with AFPI, middle bar of graph is with AFPi ⁇ , and right bar of graph is with AFGP). Data was normalized to the DMSO alone and is the mean (+/- SEM) of 3 replicates.
  • AFPI appears to confer the best protection to the cells in this Example as observed by an increase in cell viability as compared to the conventional cryoprotectant alone or to the conventional cryoprotectant/CHD mixture. This cumulative increase in viability is not observed in the presence of the AFPs plus a conventional cryoprotectant alone (i.e., without the CHD present).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Ceramic Products (AREA)
EP01928591A 2000-04-17 2001-04-17 Cyclohexandiol kryoprotektor verbindungen Expired - Lifetime EP1274302B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19766900P 2000-04-17 2000-04-17
US197669P 2000-04-17
PCT/US2001/012465 WO2001078505A1 (en) 2000-04-17 2001-04-17 Cyclohexanediol cryoprotectant compounds

Publications (2)

Publication Number Publication Date
EP1274302A1 true EP1274302A1 (de) 2003-01-15
EP1274302B1 EP1274302B1 (de) 2004-06-30

Family

ID=22730293

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01928591A Expired - Lifetime EP1274302B1 (de) 2000-04-17 2001-04-17 Cyclohexandiol kryoprotektor verbindungen

Country Status (8)

Country Link
US (1) US20020068360A1 (de)
EP (1) EP1274302B1 (de)
JP (1) JP2003530406A (de)
AT (1) ATE270037T1 (de)
AU (1) AU2001255433A1 (de)
DE (1) DE60104105T2 (de)
ES (1) ES2367352T3 (de)
WO (1) WO2001078505A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
EP1471887B1 (de) 2002-02-04 2010-04-21 Elan Pharma International Ltd. Arzneistoffnanopartikel mit lysozym-oberflächenstabilisator
KR100476790B1 (ko) * 2002-09-13 2005-03-16 주식회사 제넨메드 세포 저장 용액과 이를 이용한 동물 세포의 동결 및 저장방법
WO2004042856A1 (ja) * 2002-11-05 2004-05-21 Shishiai-Kabushikigaisha 燃料電池用冷却液組成物
AU2003274102B2 (en) * 2002-12-20 2007-01-25 Unilever Ip Holdings B.V. Preparation of antifreeze protein
JP2004284983A (ja) * 2003-03-20 2004-10-14 National Institute Of Advanced Industrial & Technology 含水物中における物質の凍結濃縮を抑制する方法、生理活性物質の失活を抑制する方法、および成分が均質に拡散した凍結物又は凍結乾燥物を製造する方法
WO2005006476A1 (ja) * 2003-07-11 2005-01-20 Shishiai-Kabushikigaisha 燃料電池用冷却液組成物
AU2003296103A1 (en) * 2003-10-01 2005-04-21 Shishiai-Kabushikigaisha Liquid coolant composition
JPWO2005037950A1 (ja) * 2003-10-16 2006-12-28 シーシーアイ株式会社 冷却液組成物
AU2003296135A1 (en) * 2003-12-25 2005-07-21 Shishiai-Kabushikigaisha Heat carrier composition
CN1926706B (zh) * 2004-03-24 2010-10-13 Cci株式会社 抑制燃料电池用冷却液组合物基剂氧化的方法
KR101368924B1 (ko) 2005-11-17 2014-03-04 니뽄젠야쿠코교 가부시키가이샤 세포 보존용 수용액
US12279610B2 (en) 2011-03-15 2025-04-22 Paragonix Technonogies, Inc. System for hypothermic transport of samples
US9253976B2 (en) 2011-03-15 2016-02-09 Paragonix Technologies, Inc. Methods and devices for preserving tissues
US9426979B2 (en) 2011-03-15 2016-08-30 Paragonix Technologies, Inc. Apparatus for oxygenation and perfusion of tissue for organ preservation
US12096765B1 (en) 2011-03-15 2024-09-24 Paragonix Technologies, Inc. System for hypothermic transport of samples
US9867368B2 (en) 2011-03-15 2018-01-16 Paragonix Technologies, Inc. System for hypothermic transport of samples
US8828710B2 (en) 2011-03-15 2014-09-09 Paragonix Technologies, Inc. System for hypothermic transport of samples
US11178866B2 (en) 2011-03-15 2021-11-23 Paragonix Technologies, Inc. System for hypothermic transport of samples
US8835158B2 (en) 2011-03-15 2014-09-16 Paragonix Technologics, Inc. Apparatus for oxygenation and perfusion of tissue for organ preservation
WO2013096659A1 (en) * 2011-12-20 2013-06-27 Cook General Biotechnology Llc Methods and compositions for storage of animal cells
US8785116B2 (en) 2012-08-10 2014-07-22 Paragonix Technologies, Inc. Methods for evaluating the suitability of an organ for transplant
US9560846B2 (en) 2012-08-10 2017-02-07 Paragonix Technologies, Inc. System for hypothermic transport of biological samples
USD765874S1 (en) 2014-10-10 2016-09-06 Paragonix Technologies, Inc. Transporter for a tissue transport system
KR101845715B1 (ko) * 2015-06-03 2018-04-05 (주)제노텍 동결방지제 조성물
US20220125042A1 (en) * 2017-05-17 2022-04-28 Universidade Nova De Lisboa Cryoprotectant and/or cryopreservant composition, methods and uses thereof
US20210400952A1 (en) 2017-06-07 2021-12-30 Paragonix Technologies, Inc. Apparatus for tissue transport and preservation
CA3066625A1 (en) 2017-06-07 2018-12-13 Paragonix Technologies, Inc. Apparatus for tissue transport and preservation
EP3982725A4 (de) 2019-06-11 2023-07-19 Paragonix Technologies Inc. Organtransportbehälter mit antiviraler therapie
US11632951B2 (en) 2020-01-31 2023-04-25 Paragonix Technologies, Inc. Apparatus for tissue transport and preservation
USD1031028S1 (en) 2022-09-08 2024-06-11 Paragonix Technologies, Inc. Tissue suspension adaptor
US20250064674A1 (en) 2023-08-25 2025-02-27 Paragonix Technologies, Inc. Methods and systems for cyclically inflating and deflating a lung ex-vivo
US12410408B2 (en) 2024-02-02 2025-09-09 Paragonix Technologies, Inc. Method for hypothermic transport of biological samples
USD1087382S1 (en) 2025-01-30 2025-08-05 Paragonix Technologies, Inc. Device for transporting a biological sample

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6773877B2 (en) * 1995-03-30 2004-08-10 Organ Recovery Systems, Inc. Methods of using ice-controlling molecules
DE69929071T2 (de) * 1998-09-21 2006-08-17 21St Century Medicine Inc., Cucamonga Verbesserte kälteschutzlösungen
US20030180704A1 (en) * 2002-03-19 2003-09-25 Brockbank Kelvin G.M. Ice-controlling molecules and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0178505A1 *

Also Published As

Publication number Publication date
US20020068360A1 (en) 2002-06-06
WO2001078505A1 (en) 2001-10-25
JP2003530406A (ja) 2003-10-14
ATE270037T1 (de) 2004-07-15
ES2367352T3 (es) 2011-11-02
DE60104105T2 (de) 2005-07-07
EP1274302B1 (de) 2004-06-30
DE60104105D1 (de) 2004-08-05
AU2001255433A1 (en) 2001-10-30

Similar Documents

Publication Publication Date Title
EP1274302B1 (de) Cyclohexandiol kryoprotektor verbindungen
US20020042131A1 (en) Cryopreservation method using cryoprotective composition of propanediol and a vehicle solution
EP1274301B1 (de) Neues aufwärmverfahren für cryokonservierte proben
US6395467B1 (en) Cryoprotectant solution containing dimethyl sulfoxide, an amide and ethylene glycol
US7270946B2 (en) Method for treatment of cellular materials with sugars prior to preservation
US7029839B2 (en) Methods and solutions for storing donor organs
Wowk How cryoprotectants work
CA2398614A1 (en) System for organ and tissue preservation and hypothermic blood substitution
JP3694730B2 (ja) 組織の冷却保存液
JP4947948B2 (ja) 細胞保存液
Karow Chemical cryoprotection of metazoan cells
Jeevanandam et al. University of Wisconsin solution for human donor heart preservation: initial clinical experience
EP3685665B1 (de) Verwendung einer lösung enthaltend peg zur konservierung von stammzellen
EP0551359B1 (de) Chemische zusammensetzungen
De Loecker et al. Metabolic changes in rat skin during preservation and storage in glycerol buffer at− 196° C
JP2020527601A (ja) 保存溶液
JPS6029471B2 (ja) 肝細胞の凍結方法
Jacobsen An introduction to the problems of organ cryopreservation
Madden et al. An improved method of corneal cryopreservation
Rowley Cryopreservation of Hematopoietic Cells

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021111

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20030502

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20040630

Ref country code: FR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040630

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040630

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040630

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040630

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040630

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040630

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040630

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040630

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60104105

Country of ref document: DE

Date of ref document: 20040805

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040930

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040930

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20041011

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20040630

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050417

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050417

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050417

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050430

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20050331

EN Fr: translation not filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051101

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20050417

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041130